JPRN-jRCT2033220220招募中3 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
Ei Fujikawa0 个研究点目标入组 228 人开始时间: 2022年6月23日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 228
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- •- Participants who have provided informed consent for this study
排除标准
- 未提供
研究者
相似试验
招募中
1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene AutoleucelMedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple MyelomaCTIS2023-505530-10-00Janssen - Cilag International365
进行中（未招募）
1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene AutoleucelMultiple MyelomaEUCTR2020-005521-84-ESJanssen-Cilag International NV400
尚未招募
4 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucelplasma cell myeloma10040778Multiple MyelomaNL-OMON53393Janssen-Cilag International NV6
进行中（未招募）
1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene AutoleucelMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2020-005521-84-NLJanssen-Cilag International NV400
进行中（未招募）
1 期
ong term follow-up study of gene therapy trial for X-linked Retinitis PigmentosaEUCTR2018-000425-31-Outside-EU/EEAJanssen-Cilag International NV